These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25280564)

  • 41. Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma.
    van de Winkel A; Menke V; Capello A; Moons LM; Pot RG; van Dekken H; Siersema PD; Kusters JG; van der Laan LJ; Kuipers EJ
    BMC Gastroenterol; 2011 Oct; 11():108. PubMed ID: 21977915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA Profiles of Barrett's Esophagus and Esophageal Adenocarcinoma: Differences in Glandular Non-native Epithelium.
    Drahos J; Schwameis K; Orzolek LD; Hao H; Birner P; Taylor PR; Pfeiffer RM; Schoppmann SF; Cook MB
    Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):429-37. PubMed ID: 26604271
    [TBL] [Abstract][Full Text] [Related]  

  • 43. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk.
    Dura P; van Veen EM; Salomon J; te Morsche RH; Roelofs HM; Kristinsson JO; Wobbes T; Witteman BJ; Tan AC; Drenth JP; Peters WH
    Int J Cancer; 2013 Oct; 133(7):1751-5. PubMed ID: 23504527
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetics of Barrett's: the bigger, the better.
    El-Omar EM; Jankowski J
    Am J Gastroenterol; 2012 Sep; 107(9):1342-5. PubMed ID: 22951876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TP53 mutations in malignant and premalignant Barrett's esophagus.
    Dolan K; Walker SJ; Gosney J; Field JK; Sutton R
    Dis Esophagus; 2003; 16(2):83-9. PubMed ID: 12823203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic gastroesophageal reflux disease shares genetic background with esophageal adenocarcinoma and Barrett's esophagus.
    Gharahkhani P; Tung J; Hinds D; Mishra A; ; Vaughan TL; Whiteman DC; MacGregor S;
    Hum Mol Genet; 2016 Feb; 25(4):828-35. PubMed ID: 26704365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma.
    Paulson TG; Maley CC; Li X; Li H; Sanchez CA; Chao DL; Odze RD; Vaughan TL; Blount PL; Reid BJ
    Clin Cancer Res; 2009 May; 15(10):3305-14. PubMed ID: 19417022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Barrett's esophagus and its progression to adenocarcinoma.
    Maley CC; Rustgi AK
    J Natl Compr Canc Netw; 2006 Apr; 4(4):367-74. PubMed ID: 16569389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic variants in Barrett's esophagus and esophageal adenocarcinoma: a literature review.
    Callahan ZM; Shi Z; Su B; Xu J; Ujiki M
    Dis Esophagus; 2019 Aug; 32(8):. PubMed ID: 30888413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; Pot RG; Moons LM; van Zoest KP; Hansen B; van Dekken H; Siersema PD; Kusters JG; Kuipers EJ
    J Hum Genet; 2012 Jan; 57(1):26-32. PubMed ID: 22129558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus.
    Li X; Galipeau PC; Paulson TG; Sanchez CA; Arnaudo J; Liu K; Sather CL; Kostadinov RL; Odze RD; Kuhner MK; Maley CC; Self SG; Vaughan TL; Blount PL; Reid BJ
    Cancer Prev Res (Phila); 2014 Jan; 7(1):114-27. PubMed ID: 24253313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TP53 gene mutations are rare in nondysplastic Barrett's esophagus.
    Novotna K; Trkova M; Pazdro A; Smejkal M; Soukupova A; Kodetova D; Smejkal P; Sedlacek Z
    Dig Dis Sci; 2006 Jan; 51(1):110-3. PubMed ID: 16416221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma.
    Kalatskaya I
    Ann N Y Acad Sci; 2016 Oct; 1381(1):74-91. PubMed ID: 27415609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.
    Dong LM; Kristal AR; Peters U; Schenk JM; Sanchez CA; Rabinovitch PS; Blount PL; Odze RD; Ayub K; Reid BJ; Vaughan TL
    Nutr Cancer; 2008; 60(1):39-48. PubMed ID: 18444134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
    Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.
    Chao DL; Sanchez CA; Galipeau PC; Blount PL; Paulson TG; Cowan DS; Ayub K; Odze RD; Rabinovitch PS; Reid BJ
    Clin Cancer Res; 2008 Nov; 14(21):6988-95. PubMed ID: 18980994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model.
    Sethi NS; Kikuchi O; Duronio GN; Stachler MD; McFarland JM; Ferrer-Luna R; Zhang Y; Bao C; Bronson R; Patil D; Sanchez-Vega F; Liu JB; Sicinska E; Lazaro JB; Ligon KL; Beroukhim R; Bass AJ
    Nat Genet; 2020 Feb; 52(2):219-230. PubMed ID: 32025000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.
    Murray L; Sedo A; Scott M; McManus D; Sloan JM; Hardie LJ; Forman D; Wild CP
    Gut; 2006 Oct; 55(10):1390-7. PubMed ID: 16682429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.